Researchers Compared Stem Cell Transplant Prophylaxis
A new study analyzed outcomes for 7,507 patients aged 60 and older who received stem cell transplants between 2016 and 2022.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Does current medical research provide sufficient guidance for transplant treatment choices in older adults?
Researchers analyzed 7,507 patients aged 60 and older to compare post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) for graft-versus-host disease prophylaxis. The study utilized data from the EBMT registry collected between 2016 and 2022 to determine optimal treatment paths.
Why it matters
Identifying the optimal graft-versus-host disease prophylaxis is critical for older patients undergoing reduced-intensity stem cell transplants. This research helps clarify which treatments lead to better survival outcomes in different donor scenarios.
The study included 1,418 matched sibling donors, 5,051 matched unrelated donors, and 1,038 mismatched unrelated donor patients. Researchers assessed these outcomes against reduced-intensity conditioning peripheral blood stem cell allo-HCT procedures.
The players
EBMT
The European Society for Blood and Marrow Transplantation is a non-profit organization dedicated to the advancement of stem cell transplantation.
The details
The study findings indicated that PTCy improved progression-free survival in matched sibling donors older than 65 years and enhanced overall survival in matched unrelated donor recipients. However, clinical outcomes for patients receiving mismatched unrelated donor transplants showed no significant difference between PTCy and ATG.
Timeline
The data collection period for the study spanned from 2016 to 2022.
The Big Picture
This study aligns with ongoing efforts within the EBMT registry to standardize care protocols for older populations. It provides necessary clinical evidence to refine existing transplant guidelines and improve patient safety.
For patients aged 60 and older, these findings suggest that the choice between PTCy and ATG may significantly affect survival rates depending on the type of donor. Patients should discuss these clinical nuances with their transplant specialists to better understand their specific treatment options.
The takeaway
Selecting the right graft-versus-host disease prophylaxis is a vital step in improving the success rates of stem cell transplants for older adults. Clinicians can use these findings to better tailor treatment plans based on donor availability.
What happens next
Further studies are expected to assess the long-term outcomes of these transplant prophylaxis methods.
Further reading
Learn more about advancements in Cancer treatment and research on our site.
Source note: This article includes information reported by Nature.
Live Poll
Does current medical research provide sufficient guidance for transplant treatment choices in older adults?
